

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-Q /A  
(Amendment No. 2)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2009

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

KRAIG BIOCRAFT LABORATORIES, INC.  
(Exact name of registrant as specified in Charter)

Wyoming

333-146316

83-0459707

(State or other jurisdiction of incorporation or organization)

(Commission File No.)

(IRS Employee Identification No.)

120 N. Washington Square, Suite 805,  
Lansing, Michigan 48933  
(Address of Principal Executive Offices)

(517) 336-0807  
(Issuer Telephone number)

(Former Name or Former Address if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer. See definition of "accelerated filer" and "large accelerated filer" in Rule 12b-2 of the Exchange Act (Check one):

Large Accelerated Filer  Accelerated Filer  Non-Accelerated Filer  Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.

Yes  No

State the number of shares outstanding of each of the issuer's classes of common equity, as of November 20, 2009: 513,617,410 shares of Common Stock.

---

---

---

**KRAIG BIOCRAFT LABORATORIES, INC.****FORM 10-Q /A  
September 30, 2009  
INDEX****PART I-- FINANCIAL INFORMATION**

Item 1. Financial Statements	1
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3. Quantitative and Qualitative Disclosures About Market Risk	23
Item 4T. Control and Procedures	23

**PART II-- OTHER INFORMATION**

Item 1. Legal Proceedings	24
Item 1A. Risk Factors	24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3. Defaults Upon Senior Securities	24
Item 4. Submission of Matters to a Vote of Security Holders	24
Item 5. Other Information	24
Item 6. Exhibits and Reports on Form 8-K	24

**SIGNATURE**

## Explanatory Note:

Kraig Biocraft Laboratories, Inc. (the “Company”) is filing this Amendment No. 2 to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 to restate the financials. This Amendment No. 2 supersedes the changes set forth in Amendment No. 1 to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 filed on May 6, 2010.

We are amending the following items:

Part I	Financial Statements and Supplementary Data
Part I Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations
Part I Item 4T	Control and Procedures

Specifically the Company has amended the financial statements and supplementary data in the Form 10-Q to properly account for the embedded derivative liability associated with our CEO’s employment agreement. For the convenience of the reader, the Company is re-filing its Form 10-Q originally filed on November 23, 2009 (the “Original Filing”) in its entirety in this Amendment No. 2 on Form 10-Q/A. This Amendment No. 2 on Form 10-Q/A continues to speak as of the date of the Original Filing and other than with respect to items described above does not reflect events occurring after the filing of the Original Filing. Accordingly, in conjunction with reading this amendment to the Original Filing, you should also read all other filings we have made with the Securities and Exchange Commission since November 23, 2009.

---

**Item 1. Financial Information****Kraig Biocraft Laboratories, Inc.  
(A DEVELOPMENT STAGE COMPANY)****CONTENTS**

PAGE 1	CONDENSED BALANCE SHEETS AS OF SEPTEMBER 30, 2009 (UNAUDITED) (RESTATED) AND DECEMBER 31, 2008 (RESTATED).
PAGE 2	CONDENSED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2009 (RESTATED) AND 2008 AND FOR THE PERIOD APRIL 25, 2006 (INCEPTION) TO SEPTEMBER 30, 2009 (UNAUDITED) (RESTATED).
PAGES 3 - 4	CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT FOR THE PERIOD FROM APRIL 25, 2006 (INCEPTION) TO SEPTEMBER 30, 2009 (UNAUDITED) (RESTATED).
PAGE 5	CONDENSED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2009 (RESTATED) AND 2008 AND FOR THE PERIOD APRIL 25, 2006 (INCEPTION) TO SEPTEMBER 30, 2009 (UNAUDITED) (RESTATED).
PAGES 6 - 19	NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) AS RESTATED – NOTE 2

**Kraig Biocraft Laboratories, Inc.**  
**(A Development Stage Company)**  
**Condensed Balance Sheets**

**ASSETS**

	<b>September 30, 2009</b>	<b>December 31, 2008</b>
	<b>(Unaudited)</b>	<b>(Restated)</b>
	<b>(Restated)</b>	<b>(Restated)</b>
<b>Current Assets</b>		
Cash	\$ 34,119	\$ 9,537
Other receivables	23,900	-
Prepaid Expenses	5,644	3,123
<b>Total Assets</b>	<b>\$ 63,663</b>	<b>\$ 12,660</b>

**LIABILITIES AND STOCKHOLDERS' DEFICIT**

<b>Current Liabilities</b>		
Accounts payable	\$ 76,650	\$ 65,750
Royalty agreement payable - related party	105,000	120,000
Accrued Expenses - related party	568,252	365,211
Derivative Liability	251,729	-
Derivative Liability- related party	3,029,291	1,361,052
<b>Total Current Liabilities</b>	<b>4,030,922</b>	<b>1,912,013</b>
<b>Long Term Liabilities</b>		
Convertible note payable - net of debt discount	4,059	-
<b>Total Liabilities</b>	<b>4,034,981</b>	<b>1,912,013</b>
<b>Commitments and Contingencies</b>	-	-
<b>Stockholders' Deficit</b>		
Preferred stock, no par value; unlimited shares authorized, none issued and outstanding	-	-
Common stock Class A, no par value; unlimited shares authorized, 502,495,099 and 499,348,500 shares issued and outstanding, respectively	821,050,	779,050
Common stock Class B, no par value; unlimited shares authorized, no shares issued and outstanding	-	-
Common Stock Issuable, 1,122,311 and 400,000 shares, respectively	22,000	4,000
Additional paid-in capital	42,060	42,060
Deficit accumulated during the development stage	(4,856,428)	(2,724,463)
<b>Total Stockholders' Deficit</b>	<b>(3,971,318)</b>	<b>(1,899,353)</b>
<b>Total Liabilities and Stockholders' Deficit</b>	<b>\$ 63,663</b>	<b>\$ 12,660</b>

See accompanying notes to condensed unaudited financial statements.



**Kraig Biocraft Laboratories, Inc.**  
**(A Development Stage Company)**  
**Condensed Statements of Operations**  
**(Unaudited)**

	For the Three Months Ended		For the Nine Months Ended		For the
	September	September	September	September	Period from
	30,	30,	30,	30,	April 25,
	2009	2008	2009	2008	2006
	(Restated)		(Restated)		(Inception)
					to
					September
					30, 2009
					(Restated)
<b>Revenue</b>	\$ -	\$ -	\$ -	\$ -	\$ -
<b>Operating Expenses</b>					
General and Administrative	12,785	8,383	38,235	57,831	160,938
Professional Fees	6,785	4,765	22,824	27,211	103,649
Officer's Salary	55,154	52,905	173,935	164,669	846,433
Contract Settlement	-	-	-	-	107,143
Research and Development	5,946	5,945	63,854	27,131	438,863
<b>Total Operating Expenses</b>	<u>80,670</u>	<u>71,998</u>	<u>298,848</u>	<u>276,842</u>	<u>1,657,026</u>
<b>Loss from Operations</b>	(80,670)	(71,998)	(298,848)	(276,842)	(1,657,026)
<b>Other Income/(Expenses)</b>					
Other income	-	-	-	2,781	2,781
Amortization of Debt Discount	(4,059)	-	(4,059)	-	(4,059)
Change in fair value of embedded derivative liability	(131,729)	-	(131,729)	-	(131,729)
Change in fair value of embedded derivative liability-related party	543,456	-	(1,668,239)	-	(3,029,291)
Interest expense	(10,898)	-	(29,090)	-	(37,104)
<b>Total Other Income/(Expenses)</b>	<u>396,770</u>	<u>-</u>	<u>(1,833,117)</u>	<u>2,781</u>	<u>(3,199,402)</u>
<b>Net (Income) Loss before Provision for Income Taxes</b>	316,100	(71,998)	(2,131,965)	(274,061)	(4,856,428)
<b>Provision for Income Taxes</b>	-	-	-	-	-
<b>Net Income (Loss)</b>	<u>\$ 316,100</u>	<u>\$ (71,998)</u>	<u>\$ (2,131,965)</u>	<u>\$ (274,061)</u>	<u>\$ (4,856,428)</u>
<b>Net Income (Loss) Per Share - Basic and Diluted</b>	<u>\$ 0.00</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	
<b>Weighted average number of shares outstanding during the period - Basic and Diluted</b>	<u>502,998,686</u>	<u>499,748,500</u>	<u>500,837,646</u>	<u>499,727,990</u>	

See accompanying notes to condensed unaudited financial statements.



**Kraig Biocraft Laboratories, Inc.**  
**(A Development Stage Company)**  
**Condensed Statement of Changes in Stockholders Deficit**  
**For the period from April 25, 2006 (inception) to September 30, 2009**  
**(Unaudited) (Restated)**

	Preferred Stock		Common Stock - Class A		Common Stock - Class B		Common Stock - To be issued		APIC	Deficit Accumulated during Development Stage	
	Shares	Par	Shares	Par	Shares	Par	Shares	Par		Stage	Total
Balance, April 25, 2006	-	\$ -	-	\$ -	-	\$ -	-	\$ -	\$ -	\$ -	\$ -
Stock issued to founder	-	-	332,292,000	180	-	-	-	-	-	-	180
Stock issued for services (\$0.01/share)	-	-	17,500,000	140,000	-	-	-	-	-	-	140,000
Stock issued for services (\$0.01/share)	-	-	700,000	5,600	-	-	-	-	-	-	5,600
Stock contributed by shareholder	-	-	(11,666,500)	-	-	-	-	-	-	-	-
Stock issued for cash (\$0.05/share)	-	-	4,000	200	-	-	-	-	-	-	200
Stock issued for cash (\$0.05/share)	-	-	4,000	200	-	-	-	-	-	-	200
Fair value of warrants issued	-	-	-	-	-	-	-	-	126,435	-	126,435
Net Loss	-	-	-	-	-	-	-	-	-	(530,321)	(530,321)
Balance, December 31, 2006	-	-	338,833,500	146,180	-	-	-	-	126,435	(530,321)	(257,706)
Stock issued for cash (\$0.01/share)	-	-	1,750,000	15,000	-	-	-	-	-	-	15,000
Stock issued for cash (\$0.01/share)	-	-	12,000,000	103,000	-	-	-	-	-	-	103,000
Stock issued for cash (\$0.0003/share)	-	-	9,000,000	3,000	-	-	-	-	-	-	3,000

Stock issued for cash (\$.01/share)	-	-	1,875,000	15,000	-	-	-	-	-	-	15,000
Stock issued for cash (\$.01/share)	-	-	1,875,000	15,000	-	-	-	-	-	-	15,000
Stock issued for services (\$.01/share)	-	-	2,000,000	16,000	-	-	-	-	-	-	16,000
Stock issued for cash (\$.01/share)	-	-	13,125,000	105,000	-	-	-	-	-	-	105,000
Stock issued for cash (\$.003/share)	-	-	80,495,000	241,485	-	-	-	-	-	-	241,485
Stock issued for cash (\$.003/share)	-	-	200,000	600	-	-	-	-	-	-	600
Stock issued for cash (\$.003/share)	-	-	8,300,000	24,900	-	-	-	-	-	-	24,900

Stock issued for cash (\$.003/share)	-	-	25,000	75	-	-	-	-	-	-	75	
Stock issued for cash (\$.003/share)	-	-	120,000	360	-	-	-	-	-	-	360	
Stock issued for cash (\$.003/share)	-	-	1,025,000	3,075	-	-	-	-	-	-	3,075	
Stock issued in connection to cash offering	-	-	28,125,000	84,375	-	-	-	-	(84,375)	-	-	
Stock issued for services (\$.01/share)	-	-	600,000	6,000	-	-	-	-	-	-	6,000	
Net loss, for the year ended December 31, 2007	-	-	-	-	-	-	-	-	-	(472,986)	(472,986)	
Balance, December 31, 2007	-	-	499,348,500	779,050	-	-	-	-	42,060	(1,003,307)	(182,197)	
Stock issuable for services (\$.01/share)	-	-	-	-	-	-	400,000	4,000	-	-	4,000	
Net loss, for the year ended December 31, 2008	-	-	-	-	-	-	-	-	-	(1,721,156)	(1,712,156)	
Balance, December 31, 2008	-	-	499,348,500	779,050	-	-	400,000	4,000	42,060	(2,724,463)	(1,899,353)	
Stock issued for cash (\$.01/share)	-	-	2,500,000	25,000	-	-	-	-	-	-	25,000	
Stock issued for cash (\$.008/share)	-	-	366,599	3,000	-	-	-	-	-	-	3,000	
Stock issued for services	-	-	280,000	14,000	-	-	722,311	18,000	-	-	32,000	
Net loss for the period ended September 30, 2009	-	-	-	-	-	-	-	-	-	(2,131,965)	(2,131,965)	
<b>Balance, September 30, 2009</b>	<b>-</b>	<b>\$ -</b>	<b>502,495,099</b>	<b>821,050</b>	<b>-</b>	<b>\$ -</b>	<b>1,122,311</b>	<b>\$22,000</b>	<b>\$ ,060</b>	<b>42</b>	<b>( (</b>	<b>( (</b>
										<b>4,856,428)</b>	<b>\$3,971,318)</b>	

See accompanying notes to condensed unaudited financial statements.



**Kraig Biocraft Laboratories, Inc.**  
**(A Development Stage Company)**  
**Condensed Statements of Cash Flows**  
**(Unaudited)**

	<b>For the Nine Months Ended September 30,</b>		<b>For the Period from April 25, 2006 (Inception) to September 30, 2009</b>
	<b>2009</b>	<b>2008</b>	
	<b>(Restated)</b>		<b>(Restated)</b>
<b>Cash Flows From Operating Activities:</b>			
Net Loss	\$ (2,131,965)	\$ (274,061)	\$ (4,856,428)
Adjustments to reconcile net loss to net cash used in operations			
Stock issuable for services	18,000	4,000	22,000
Change in Fair Value of Derivative Liability	1,799,968	-	3,161,020
Stock issued for services	14,000	-	181,780
Amortization of debt discount	4,059	-	4,059
Warrants issued to employees	-	-	126,435
Changes in operating assets and liabilities:			
(Increase)Decrease in prepaid expenses	(2,521)	6,706	(5,644)
(Increase)Decrease in other receivables	(23,900)	-	(23,900)
Increase in accrued expenses and other payables - related party	203,041	26,805	568,252
(Decrease) Increase in royalty agreement payable - related party	(15,000)	120,000	105,000
Increase in accounts payable	10,900	32,238	76,650
<b>Net Cash Used In Operating Activities</b>	<b><u>(123,418)</u></b>	<b><u>(84,312)</u></b>	<b><u>(640,776)</u></b>
<b>Cash Flows From Financing Activities:</b>			
Proceeds from Notes Payable - Stockholder	-	-	10,000
Repayments of Notes Payable - Stockholder	-	-	(10,000)
Proceeds from issuance of convertible note	120,000	-	120,000
Proceeds from issuance of common stock	28,000	-	554,895
<b>Net Cash Provided by Financing Activities</b>	<b><u>148,000</u></b>	<b><u>-</u></b>	<b><u>674,895</u></b>
<b>Net Increase (Decrease) in Cash</b>	<b>24,582</b>	<b>(84,312)</b>	<b>34,119</b>
Cash at Beginning of Period	<u>9,537</u>	<u>105,818</u>	<u>-</u>
<b>Cash at End of Period</b>	<b><u>\$ 34,119</u></b>	<b><u>\$ 21,506</u></b>	<b><u>\$ 34,119</u></b>
<b>Supplemental disclosure of cash flow information:</b>			
Cash paid for interest	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>
Cash paid for taxes	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

**SUPPLEMENTAL DISCLOSURE OF NON CASH ITEMS**

During the period ended December 31, 2006, the principal stockholder contributed 11,666,500 shares of common stock to the Company as an in kind contribution of stock. The shares were retired by the Company.

issue additional common shares under the stock purchase agreement for any subsequent issuance at a price below \$.08 per share for a period of 12 months. The Company has issued 28,125,000 additional shares through September 2007 as a result of the subsequent stock issuances in the amount of \$84,375 (\$.003/share).

See accompanying notes to condensed unaudited financial statements.

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

**NOTE 1        SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION**

*(A) Basis of Presentation*

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations.

It is management's opinion, however that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statements presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year.

Activities during the development stage include developing the business plan and raising capital.

*(B) Use of Estimates*

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.

*(C) Cash*

For purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.

*(D) Income/(Loss) Per Share*

Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by FASB Accounting Standards Codification No. 260, "Earnings per Share." As of September 30, 2009 and 2008, 6,000,000 and 0 warrants were not included in the computation of income/(loss) per share and 218,386,746 and 0 shares issuable upon conversion of notes payable were not included in the computation of income/(loss) per share because their inclusion is anti-dilutive.

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**

**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

***(E) Research and Development Costs***

The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation.

***(F) Income Taxes***

The Company accounts for income taxes under the FASB Accounting Standards Codification No. 740, *Income Taxes*. Under FASB Accounting Standards Codification No. 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB Accounting Standards Codification No. 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

***(G) Stock-Based Compensation***

In December 2004, the FASB issued FASB Accounting Standards Codification No. 718, *Compensation – Stock Compensation*. Under FASB Accounting Standards Codification No. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. The Company applies this statement prospectively.

Equity instruments (“instruments”) issued to other than employees are recorded on the basis of the fair value of the instruments, as required by FASB Accounting Standards Codification No. 718. FASB Accounting Standards Codification No. 505, *Equity Based Payments to Non-Employees* defines the measurement date and recognition period for such instruments. In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification.

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

***(H) Business Segments***

The Company operates in one segment and therefore segment information is not presented.

***(I) Recent Accounting Pronouncements***

In May 2009, the FASB issued FASB Accounting Standards Codification No. 855, *Subsequent Events*. FASB Accounting Standards Codification No. 855 establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. FASB Accounting Standards Codification No. 855 sets forth (1) The period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements, (2) The circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements and (3) The disclosures that an entity should make about events or transactions that occurred after the balance sheet date. FASB Accounting Standards Codification No. 855 is effective for interim or annual financial periods ending after September 15, 2009. The adoption of this FASB Accounting Standards Codification No. did not have a material effect on the Company's financial statements.

In June 2009, the FASB issued FASB Accounting Standards Codification No. 860, *Transfers and Servicing*. FASB Accounting Standards Codification No. 860 improves the relevance, representational faithfulness, and comparability of the information that a reporting entity provides in its financial statements about a transfer of financial assets; the effects of a transfer on its financial position, financial performance, and cash flows; and a transferor's continuing involvement, if any, in transferred financial assets. FASB Accounting Standards Codification No. 860 is effective as of the beginning of each reporting entity's first annual reporting period that begins after November 15, 2009, for interim periods within that first annual reporting period and for interim and annual reporting periods thereafter. The Company is evaluating the impact the adoption that FASB Accounting Standards Codification No. 860 will have on its financial statements.

In June 2009, the FASB issued FASB Accounting Standards Codification No. 810, *Consolidation*. FASB Accounting Standards Codification No. 810 improves financial reporting by enterprises involved with variable interest entities. FASB Accounting Standards Codification No. 810 is effective as of the beginning of each reporting entity's first annual reporting period that begins after November 15, 2009, for interim periods within that first annual reporting period, and for interim and annual reporting periods thereafter. The Company is evaluating the impact the adoption of FASB Accounting Standards Codification No. 810 will have on its financial statements.

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

In June 2009, the FASB issued FASB Accounting Standards Codification No. 105, *GAAP*. The FASB Accounting Standards Codification ("Codification") will be the single source of authoritative nongovernmental U.S. generally accepted accounting principles. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. FASB Accounting Standards Codification No. 105 is effective for interim and annual periods ending after September 15, 2009. All existing accounting standards are superseded as described in FASB Accounting Standards Codification No. 105. All other accounting literature not included in the Codification is nonauthoritative. The adoption of the Codification did not have a significant impact on the Company's financial statements.

***(J) Reclassification***

The 2008 financial statements have been reclassified to conform to the 2009 presentation.

***(K) Derivative Financial Instruments***

Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.

Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.

***(L) Fair Value Accounting***

We measure our financial assets and liabilities in accordance with generally accepted accounting principles. For certain of our financial instruments, including cash, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, also approximate fair value because current interest rates available to us for debt with similar terms and maturities are substantially the same.

Effective January 1, 2008, we adopted fair value accounting guidance for financial assets and liabilities (ASC 820). The adoption did not have a material impact on our results of operations, financial position or liquidity. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

Level

- LEVEL
- 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
- Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

We currently measure and report at fair value the liability for warrant and embedded conversion option derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing Black-Scholes option pricing model. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2009:

Liabilities	Balance at September 30, 2009	Quoted Prices		
		in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Fair value of liabilities for warrant derivative instruments	\$ 119,909	\$ -	\$ -	\$ 119,909
Fair value of liability for embedded conversion option derivative instruments	\$ 3,029,291	\$ -	\$ -	\$ 3,029,291
Fair value of liability for embedded conversion option derivative instruments	\$ 131,820	\$ -	\$ -	\$ 131,820
Total Financial Liabilities	\$ 3,281,020	\$ -	\$ -	\$ 3,281,020

## Note 2 RESTATEMENT

On May 20, 2010, the Company determined that it had not properly accounted for a derivative as liability as required by FASB Accounting Standards Codification No. 480, Accounting for certain Financial Instruments with Characteristics of both Liabilities and Equity. As a result of these adjustments, the Company was required to restate its financial statements and amend its 10Q for the period ended September 30, 2009 with a decrease in the fair value of embedded derivative liability of \$131,727 for three and nine months ending September 30, 2009, and an increase in the fair value of embedded derivative liability - related party of \$1,361,052 for the nine months ending September 30, 2009. The company also determined that it \$131,727 for the three and nine months ending September 30, 2009, and an increase in the fair value of embedded derivative liability - related party of \$1,361,052 for the nine months ending September 30, 2009. The Company also determined that it had not properly accounted for a Stock dividend effected in the form of a stock Split. As a result of these adjustments, the company was required to restate its financial statements and amend its 10Q for the period ending September 30, 2009 with a decrease in common stock \$8,245,850 and a decrease in deficit accumulated during the development stage of \$8,245,850. The net decrease in deficit accumulated during the development stage is \$8,114,121 as a result of these two restatements. Additional paid in capital was decreased by \$ 120,000 to fix a typographical error noted on the September 30, 2009 10Q as originally filed.

	September 30, 2009		
	As		
	previously Reported	Adjustments	As Restated
Common Stock	\$ 9,066,900	\$ (8,245,850)	\$ 821,050
Additional paid-In Capital	\$ 162,060	\$ (120,000)	\$ 42,060
Deficit Accumulated during the development stage	\$ (12,970,549)	\$ 8,114,121	\$ (4,856,428)
Total Stockholder's Deficit	\$ (3,719,589)	\$ (251,729)	\$ (3,917,318)

	For the three months Ended September 30, 2009		for the nine months Ended September 30, 2009			for the Period form April 25,2006 (Inception) to September 30, 2009		
	As		As			As		
	Previously Reported	Adjustments Restated	Previously Reported	Adjustments Restated	As Restated	Previously Reported	Adjustment Restated	As Restated
Change in fair								

value of  
embedded  
derivative  
liability

\$ — \$ (131,729) \$(131,729) \$ — \$ (131,729) \$ (131,729) \$ — \$ (131,729) \$ (131,729)

Change in fair  
value of  
embedded  
derivative  
liability-  
related party

\$ 543,456 \$ — \$ 543,456 \$(3,029,291) \$ 1,361,052 \$(1,668,239) \$(3,029,291) \$ — \$ 3,029,291

Net  
Income/(Loss)  
before Inome  
Taxes

\$ 447,829 \$ (131,729) \$ 316,100 \$(3,361,288) \$ 1,229,323 \$(2,131,965) \$(4,724,699) \$ (131,729) \$(4,856,428)

Provision for  
Income Taxes

\$ — \$ — \$ — \$ — \$ — \$ — \$ — \$ — \$ — \$ —

Net

Income/(Loss) \$ 447,829 \$ (131,729) \$ 316,100 \$(3,361,288) \$ 1,229,323 \$(2,131,965) \$(4,724,699) \$ (131,729) \$(4,856,428)

### NOTE 3 GOING CONCERN

As reflected in the accompanying unaudited financial statements, the Company is in the development stage, has a working capital deficiency of \$ 3,967,259 and stockholders deficiency of \$ 3,971,318 and used \$640,776 of cash in operations from inception. This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company's ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

### NOTE 4 OTHER RECEIVABLE

As of September 30, 2009 the Company is owed \$23,900 for the overpayment of research and development fees. The refund was received on November 3, 2009 (See Note 7(B) and 9).

### NOTE 5 CONVERTIBLE DEBT

On July 17, 2009, the Company entered into an agreement with an investor group where the Company will issue up to \$120,000 in convertible units. The debentures will be in the face amount of \$10,000 each, mature on December 31, 2010, bear interest at the rate of 5% simple interest per annum, payable at maturity or convertible with the principal, and the principal and interest shall be convertible at the option of the holder at a fixed price of \$0.018 per share. Each debenture shall have a warrant attached exercisable for the purchase of 500,000 shares of common stock. The warrants shall expire on December 31,

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

2011, have a cashless exercise provision, and be exercisable at a fixed price of \$0.02. The agreement also requires the investment group to purchase up to \$1,000,000 of common stock monthly at the lesser of \$75,000 or 200% of the average daily volume multiplied by the average of the daily closing prices for the ten days immediately preceding the exercise date. Each investment by the investment group is priced at the lowest closing "bid" price of the common stock during the five days immediately before the investment. The term of the funding shall be the earlier of (a) the drawing down of the entire \$1,000,000 or (b) 24 months after the Effective Date, July 17, 2011. In addition, the Company is required to file and maintain an effective registration statement covering the convertible units, cannot issue more than 5% of its common stock outstanding without the investor group's consent and must maintain a contractual relationship with a public relations firm. The Company has issued \$120,000 of convertible debt to date.

In connection with convertible debt issued, the Company has determined that an allocation of fair value associated with these warrants is applicable for these conventional convertible debt instruments. The Company first determined the fair value of the warrants based upon the following management assumptions:

**Table 1** **Black Scholes Inputs for the Convertible Debt and Derivative Financial Instruments**

**Warrants**

	<b>Issuance of Warrants – September 14, 2009</b>	<b>As of September 30, 2009</b>
Expected Volatility	448.66%	448.62%
Expected Term	2.3 years	2.25 years
Expected Dividends	0%	0%
Risk Free Interest Rate	1.49%	1.45%

	<b>Issuance of Convertible Note</b>	<b>As of September 30, 2009</b>
<b>Embedded Conversion Options</b>		
Volatility	448.66%	448.62%
Expected Term	1.3 years	1.25 years
Expected Dividends	0%	0%
Risk Free Interest Rate	1.49%	1.45%

The Company calculated the fair values of the liabilities for embedded conversion option derivative instruments at September 14, 2009 with the Black-Scholes option pricing model using the closing price of the Company's common stock, \$0.02 and the ranges for volatility, expected term and risk free interest indicated in Table 1 above. The fair value of the embedded conversion options at the commitment date was \$251,919. Of the total, \$120,000 was assigned to debt discount and \$131,919 was recorded as a derivative expense.

The Company calculated the estimated fair values of the liabilities for warrant derivative instruments at September 14, 2009 and September 30, 2009 with the Black-Scholes option pricing model using the closing price of the Company's common stock, \$0.02 and \$0.02, respectively, and the ranges for volatility, expected term and risk free interest indicated in Table 1 above. The fair value of the warrant liability at September 14, 2009 and September 30, 2009 was approximately \$119,900.

The Company calculated the estimated fair values of the liabilities for embedded conversion option derivative instruments at September 30, 2009 with the Black-Scholes option pricing model using the closing price of the Company's common stock, \$0.02 and the ranges for volatility, expected term and risk free interest indicated in Table 1 above.

The following table summarizes convertible note payable outstanding as of September 30, 2009:

	<b>Conventional Debt</b>	
Conventional debt	\$	120,000
Less: debt discount	\$	115,941
Conventional debt, net of debt \$ discount		4,059

At September 30, 2009, the Company recorded interest expense and related accrued interest payable of \$263. The Company also recorded \$4,059 for the amortization of debt discount in interest expense on the statement of operations. The debt discount is being amortized over the life of the convertible debt.

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

**NOTE 6**      **STOCKHOLDERS' DEFICIT**

*(A) Common Stock Issued for Cash*

On April 28, 2006, the Company issued 8,000 shares of common stock for cash of \$400 (\$0.05 per share).

On January 8, 2007 the Company issued 1,750,000 shares of common stock for \$15,000 (\$0.01/share). This agreement was subsequently terminated effective May 23, 2007.

On January 22, 2007 the Company issued 12,000,000 shares of common stock for \$103,000 (\$0.01/share). In addition, 9,000,000 shares were issued for \$3,000 (\$0.0003/share).

On April 4, 2007, the Company issued 1,875,000 shares of common stock for cash of \$15,000 (\$0.01 per share).

On April 20, 2007, the Company issued 1,875,000 shares of common stock for cash of \$15,000 (\$0.01 per share).

On May 18, 2007, the Company issued 13,125,000 shares of common stock for cash of \$105,000 (\$0.01 per share).

On August 28, 2007 the Company entered into a stock purchase agreement to issue 80,495,000 shares common stock in the amount of \$241,485 (\$0.003/share).

On August 29, 2007 the Company entered into a stock purchase agreement to issue 200,000 shares common stock in the amount of \$600 (\$0.003/share).

On August 29, 2007 the Company entered into a stock purchase agreement to issue 8,300,000 shares common stock in the amount of \$24,900 (\$0.003/share).

On September 1, 2007 the Company entered into a stock purchase agreement to issue 25,000 shares common stock in the amount of \$75 (\$0.003/share).

On September 5, 2007 the Company entered into a stock purchase agreement to issue 120,000 shares common stock in the amount of \$360 (\$0.003/share).

On September 12, 2007 the Company entered into a stock purchase agreement to issue 1,025,000 shares common stock in the amount of \$3,075 (\$0.003/share).

In accordance with the May 2007 stock purchase agreement which contains an anti-dilution clause which requires the Company to issue additional common shares under the stock purchase agreement for any subsequent issuance at a price below \$.08 per share for a period of 12 months, the Company has issued 28,125,000 additional shares through September 2007 as a result of the subsequent stock issuances at \$0.003/share.

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

On April 24, 2009 the Company issued 2,000,000 shares of common stock for \$20,000 (\$0.01/share).

On May 22, 2009, the Company issued 500,000 shares of common stock for \$5,000 (\$0.01/share).

On September 30, 2009, the Company issued 366,599 shares of common stock for \$3,000 (\$0.008/share).

***(B) Common Stock Issued for Intellectual Property***

On April 26, 2006, the Company issued 332,292,000 shares of common stock to its founder having a fair value of \$180 (\$0.000001/share) in exchange for intellectual property. The fair value of the patent was determined based upon the historical cost of the intellectual property contributed by the founder.

***(C) Common Stock Issued for Services***

On May 8, 2006, the Company entered into a license agreement for research and development. Pursuant to the terms of the agreement, the Company issued 17,500,000 shares of common stock upon execution of the agreement. The Company also received a five-year call option from the license holder to repurchase 7,000,000 common shares at an exercise price of \$150,000 or \$.02 per share. The option gives the Company the right, but not the obligation to repurchase the shares of common stock. The call option expires May 4, 2011. As of September 30, 2009 the value of the stock was \$.02 per share. However, the Company does not have the obligation to repurchase the shares.

On July 1, 2006 the Company entered into a five year consulting agreement for research and development. Pursuant to the terms of the agreement, the Company paid 700,000 shares of common stock upon execution. These shares had a fair value of \$5,600 (\$0.01/share) based upon the recent cash offering price. Additionally, 2,000,000 shares of common stock were issued on May 18, 2007 with a fair value of \$16,000 (\$0.01/share). As of December 31, 2008, the Company issued 600,000 shares of common stock for consulting services rendered with a fair value of \$6,000 (\$0.01/share). On January 15, 2008 the Company authorized the issuance of 400,000 shares of common stock for consulting services rendered with a fair value of \$4,000 (\$0.01/share).

On July 1, 2009, the issuance of 280,000 shares was approved by the board of directors as repayment for services previously provided to the Company by a consultant having a fair value of \$14,000 (\$0.05/share) in accordance with a consulting agreement (See Note 7 (C)).

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

On July 1, 2009, the issuance of 482,825 shares was approved by the board of directors as partial payment for services previously provided to the Company by a consultant in accordance with a consulting agreement. The total amount of issuable shares for the consultant is 1,122,311 shares, which includes 400,000 issuable shares previously approved by the board of directors and 239,486 shares will be issued in November 2009 (See Note 7 (C) and 9).

***(D) Cancellation and Retirement of Common Stock***

On December 29, 2006, the Company's founder returned 11,666,500 shares of common stock to the Company. These shares were cancelled and retired. Accordingly, the net effect on equity is \$0.

***(E) Common Stock Warrants***

During 2006, the Company issued 4,200,000 warrants to an officer under his employment agreement. The Company recognized an expense of \$126,435 for the period from inception to December 31, 2006. The Company recorded the fair value of the warrants based on the fair value of each warrant grant estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in 2006, dividend yield of zero, expected volatility of 183%; risk-free interest rates of 4.98%, expected life of one year. The warrants vested immediately. The options expire between 5 and 9 years from the date of issuance and have an exercise price of between \$.21 and \$.40 per share. During November 2006, the Company and the officer entered into an amendment to the employment agreement whereby all the warrants were retired.

The following table summarizes information about warrants for the Company as of September 30, 2009.

<b>2009 Warrants Outstanding</b>				<b>Options Exercisable</b>	
<b>Range of Exercise Price</b>	<b>Number Outstanding at September 30, 2009</b>	<b>Weighted Average Remaining Contractual Life</b>	<b>Weighted Average Exercise Price</b>	<b>Number Exercisable at September 30, 2009</b>	<b>Weighted Average Exercise Price</b>
\$ 0.02	6,000,000	2.25	\$ 0.02	6,000,000	\$ 0.02

***(F) Amendment to Articles of Incorporation***

On February 16, 2009, the Company amended its articles of incorporation to amend the number and class of shares the Company is authorized to issue as follows:

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

- Common stock Class A, unlimited number of shares authorized, no par value
- Common stock Class B, unlimited number of shares authorized, no par value
- Preferred stock, unlimited number of shares authorized, no par value

*(G) Stock Split Effected in the Form of a Stock Dividend*

On March 23, 2009, the Company's Board of Directors declared a nine-for-one stock split to be effected in the form of a stock dividend. The stock dividend was distributed to shareholders of record as of April 27, 2009. A total of 449,773,650 shares of common stock were issued. All basic and diluted loss per share and average shares outstanding information has been adjusted to reflect the aforementioned stock dividend.

**NOTE 7**            **COMMITMENTS AND CONTINGENCIES**

*(A) Employment Agreement*

On April 26, 2006, the Company entered into a five-year employment agreement with the Company's Chairman and Chief Executive Officer. The agreement renews annually so that at all times, the term of the agreement is five years. Pursuant to this agreement, the Company will pay an annual base salary of \$185,000 for the period May 1, 2006 through December 31, 2006. Base pay will be increased each January 1st, for the subsequent twelve month periods by nine percent. The officer will also be entitled to life, disability, health and dental insurance. In addition, the officer received 700,000 five year warrants at an exercise price of \$.21 per share, 1,500,000 eight year warrants at an exercise price of \$.33 per share and 2,000,000 nine year warrants at an exercise price of \$.40 per share (See Note 4(E)). The warrants fully vested on the date of grant. The agreement also calls for the issuance of warrants and increase in the officer's base compensation upon the Company reaching certain milestones:

1. Upon the Company's successful laboratory development of a new silk fiber composed of one or more proteins that are exogenous to a host, the Company will issue 500,000 eight year warrants at an exercise price of \$.20 per share and raise executive's base salary by 14%.
2. Upon the Company's successful laboratory development of a new silk fiber composed of two or more proteins that are exogenous to a host, the Company will issue 600,000 eight year warrants at an exercise price of \$.18 per share and raise executive's base salary by 15%.
3. Upon the Company's successful laboratory development of a new silk fiber composed of at least in part of one or more synthetic proteins, the Company will issue 900,000 eight year warrants at an exercise price of \$.18 per share and raise executive's base salary by 18%.

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**

**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

4. Upon the Company's successful laboratory development of a new silk fiber composed of at least in part of one or more proteins that are genetic modifications or induced mutations of a host silk protein, the Company will raise the executive's base salary by 8%.
5. Upon the Company becoming either a registered company or upon its stock trading and the company achieving a market capitalization in excess of \$35 million for over 120 calendar day period, the executive's base salary will increase to \$225,000.
6. Upon the Company becoming either a registered company or upon its stock trading and the company achieving a market capitalization in excess of \$65 million for over 91 calendar day period, the executive's base salary will increase to \$260,000.
7. Upon the Company becoming either a registered company or upon its stock trading and the company achieving a market capitalization in excess of \$100 million for over 91 calendar day period, the executive's base salary will increase to \$290,000.
8. Upon the Company becoming either a registered company or upon its stock trading and the company achieving a market capitalization in excess of \$200 million for over 120 calendar day period, the executive's base salary will increase to \$365,000.
9. Upon the Company becoming either a registered company or upon its stock trading and the company achieving a market capitalization in excess of \$350 million for over 150 calendar day period, the executive's base salary will increase to \$420,000.

On November 6, 2006, the Company entered into an addendum to the employment agreement whereby the officer agreed to retire all stock warrants issued or to be issued under his employment agreement in return for an increase in his severance allowance to \$600,000 or seventy five percent of total salary due under the remaining term of the employment agreement, which ever is greater and a death benefit of \$300,000 or thirty five percent of the total salary due under the remaining term of the employment agreement.

In addition, upon expiration or termination of the employment agreement, the Company agrees to keep the officer employed as a consultant for a period of nine years at a rate of \$4,000 per month with annual increases of 3%. The agreement also calls for certain increases based on milestones reached by the company, including:

1. If the company achieves gross sales exceeding \$10 million or net income exceeding \$1 million for any two years within the ten year period after the date of this agreement or a market capitalization in excess of \$45 million for over 180 calendar days within nine years from the date of this agreement, the term of the consulting agreement will be extended to 10 years.



**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

2. If the company achieves gross sales exceeding \$19 million or net income exceeding \$3 million for any two years within the twelve year period after the date of this agreement or a market capitalization in excess of \$65 million for over 180 calendar days within nine years from the date of this agreement, the term of the consulting agreement will be extended to 20 years or the life of the officer and his spouse at a rate of \$6,500 per month with a 3% annual increase.

3. If the company achieves gross sales exceeding \$38 million or net income exceeding \$6 million for any two years within the twelve year period after the date of this agreement or a market capitalization in excess of \$120 million for over 180 calendar days within nine years from the date of this agreement, the term of the consulting agreement will be extended to 20 years or the life of the officer and his spouse at a rate of \$10,000 per month with a 3% annual increase.

4. If the company achieves gross sales exceeding \$59 million or net income exceeding \$9 million for any year within the twelve year period after the date of this agreement or a market capitalization in excess of \$210 million for over 180 calendar days within nine years from the date of this agreement, the term of the consulting agreement will be extended to 20 years or the life of the officer and his spouse at a rate of \$15,000 per month with a 3% annual increase.

5. If the company achieves gross sales exceeding \$78 million or net income exceeding \$12 million for any year within the twelve year period after the date of this agreement or a market capitalization in excess of \$320 million for over 180 calendar days within nine years from the date of this agreement, the term of the consulting agreement will be extended to 20 years or the life of the officer and his spouse at a rate of \$20,000 per month with a 3% annual increase.

On October 10, 2008, the Company entered into an addendum to the employment agreement whereby all unpaid back salary will accrue interest at 7% per year. At September 30, 2009, the Company recorded interest expense and related accrued interest payable of \$28,897. In addition, the Company granted the CEO the right to convert any accrued salary into Class "A" Common Stock at either 1) The lowest price at which the Company's Class "A" Common Stock has traded over the preceding twelve month period, 2) At the lowest bid price for the preceding thirty days, 3) The lowest price paid in cash for the Class "A" Common Stock during the twelve months preceding the conversion. The conversion price for all salary accrued through March 1, 2009 is the lesser of options 1-3 or \$0.002. The conversion price for all salary accrued from March 1, 2009 through September 30, 2009 is the lesser of options 1-3. As of September 30, 2009, no accrued salary has been converted to Class "A" Common Stock. As of September 30, 2009 the Company owes \$498,709 in accrued salary (See Note 8) and has accrued a derivative liability of \$3,029,291 for the potential benefit of the convertible accrued salary as per FASB Accounting Standards Codification No. 480, *Distinguishing Liabilities from Equity*. Per addendum, the lowest stock price to convert the liability was \$.002 for all accrued salary through March 1, 2009. The lowest stock price to convert the liability was \$.008 for accrued salary from March 1, 2009 through September 30, 2009. See table below for a breakdown of the derivative liability.

Date	<u>Accrued Salary</u>	<u>Conversion Rate</u>	<u>Derivative Liability</u>
3/1/2009	\$ 388,718	\$ 0.002	\$ 2,876,514
3/1/09-3/31/10	\$ 138,888	\$ 0.008	\$ 152,777

Total Derivative Liability Less Accrued Salary:

\$ 3,029,291

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

***(B)License Agreement***

On May 8, 2006, the Company entered into a license agreement. Pursuant to the terms of the agreement, the Company paid a non-refundable license fee of \$10,000. The Company will pay a license maintenance fee of \$10,000 on the one year anniversary of this agreement and each year thereafter. The Company will pay an annual research fee of \$13,700 with first payment due January 2007, then on each subsequent anniversary of the effective date commencing May 4, 2007. Pursuant to the terms of the agreement the Company may be required to pay additional fees aggregating up to a maximum of \$10,000 a year for patent maintenance and prosecution relating to the licensed intellectual property. As of September 30, 2009, the Company has made a payment of \$70,000 for the required payments of \$45,602 under the agreement and has received a refund of \$23,900 for the overpayment on November 3, 2009, which was recorded as other receivable as of September 30, 2009 (See Note 4 and 9).

***(C)Royalty and Research Agreements***

On May 1, 2008 the Company entered into a five year consulting agreement for research and development. Pursuant to the terms of the agreement, the Company will be required to pay \$1,000 per month, or at the Company's option, the consulting fee may be paid in the form of Company common stock based upon the greater of \$0.05 per share or the average of the closing price of the Company's shares over the five days preceding such stock issuance. As of June 30, 2009 the Company accrued \$14,000 of accounts payable for the services provided of which was paid in common stock on July 1, 2009 (See Note 9(C)). As of September 30, 2009, \$3,000 was accrued for services provided during the quarter.

On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with an officer. In consideration of the Company issuing either 200,000 preferred shares with the following preferences; no dividends and voting rights equal to 100 common shares per share of preferred stock or the payment of \$120,000, the officer agreed to terminate the royalty payments due under the agreement and give title to the exclusive license for the non protective apparel use of the intellectual property to the Company. On the date of the agreement, the Company did not have any preferred stock authorized with the required preferences. In accordance with FASB Accounting Standards Codification No 480, *Distinguishing Liabilities from Equity*, the Company determined that the present value of the payment of \$120,000 that was due on December 26, 2007, the one year anniversary of the addendum, should be recorded as an accrued expense until such time as the Company has the ability to assert that it has preferred shares authorized. As of September 30, 2009, the Company has recorded \$120,000 in accrued expenses- related party. On December 21, 2007 the officer extended the due date to July 30, 2008. On May 30, 2008 the officer extended the due date to December 31, 2008. On October 10, 2008, the officer extended the due date to the earlier of (a) March 30, 2010 or (b) upon demand by the officer. On September 8, 2009, a payment of \$15,000 was paid to the officer. As of September 30, 2009, the outstanding balance is \$105,000. Additionally, the accrued expenses are accruing 7% interest per year. At September 30, 2009, the Company recorded interest expense and related accrued interest payable of \$8,107. An additional a payment of \$10,000 was made on October 19, 2009 (See Note 8 and 9).

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

On February 1, 2007 the Company entered into a consulting agreement for research and development for period of one year at a cost of \$150,000. In April 2008, this agreement was extended through March 31, 2009 on a cost reimbursement basis. Reimbursements are to be made quarterly and are not to exceed \$35,000. As of today, the Company is negotiating a new consulting agreement.

On July 1, 2006 the Company entered into a five year consulting agreement for research and development. Pursuant to the terms of the agreement, the Company paid 700,000 shares of common stock upon execution. These shares had a fair value of \$5,600 (\$0.01/share) based upon the recent cash offering price. Additionally, 2,000,000 shares of common stock were issued on May 18, 2007 with a fair value of \$16,000 (\$0.01/share). As of December 31, 2008, the Company issued 600,000 shares of common stock for consulting services rendered with a fair value of \$6,000 (\$0.01/share). On January 15, 2008 the Company authorized the issuance of 400,000 shares of common stock for consulting services rendered with a fair value of \$4,000 (\$0.01/share). On July 1, 2009, the issuance of 482,825 shares was approved by the board of directors as partial payment for services previously provided to the Company by a consultant in accordance with a consulting agreement. The total amount of issuable shares for the consultant is 1,122,311 shares, which includes 400,000 issuable shares previously approved by the board of directors and 239,486 shares which will be issued in November 2009 (See Note 6 (C) and 9).

***(D) Consulting Agreement***

On August 3, 2009, the Company entered into an agreement with a consultant to provide investor relations services. The Company is to issue 10,000,000 shares with a fair value of \$100,000 (\$0.01/share) to a consultant for investor relations to be provided over a term of 180 days. As of September 30, 2009, the Company and the consultant have agreed to delay the start date of the agreement to a future period. As of September 30, 2009 no shares has been issued and no services have been provided.

**NOTE 8            RELATED PARTY TRANSACTIONS**

On October 6, 2006 the Company received \$10,000 from a principal stockholder. Pursuant to the terms of the loan, the advance bears interest at 12%, is unsecured and matures on May 1, 2007. At September 30, 2009, the Company recorded interest expense and related accrued interest payable of \$776. As of September 30, 2009, the loan principle was repaid.

On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with an officer. In consideration of the Company issuing either 200,000 preferred shares with the following preferences; no dividends and voting rights equal to 100 common shares per share of preferred stock or the payment of \$120,000, the officer

**KRAIG BIOCRAFT LABORATORIES, INC.**  
**(A DEVELOPMENT STAGE COMPANY)**  
**NOTES TO FINANCIAL STATEMENTS**  
**AS RESTATED NOTE 2**  
**AS OF SEPTEMBER 30, 2009**  
**(UNAUDITED)**

agreed to terminate the royalty payments due under the agreement and give title to the exclusive license for the non protective apparel use of the intellectual property to the Company. On the date of the agreement, the Company did not have any preferred stock authorized with the required preferences. In accordance with In accordance with FASB Accounting Standards Codification No. 480, *Distinguishing Liabilities from Equity*, the Company determined that the present value of the payment of \$120,000 that was due on December 26, 2007, the one year anniversary of the addendum, should be recorded as an accrued expense until such time as the Company has the ability to assert that it has preferred shares authorized. As of September 30, 2009, the Company has recorded \$120,000 in royalty agreement payable- related party. On December 21, 2007 the officer extended the due date to July 30, 2008. On May 30, 2008 the officer extended the due date to March 31, 2009. On October 10, 2008, the officer extended the due date to the earlier of (a) March 30, 2010 or (b) upon demand by the officer. On September 8, 2009, a payment of \$15,000 was paid to the officer. As of September 30, 2009, the outstanding balance is \$105,000. Additionally, the accrued expenses are accruing 7% interest per year. At September 30, 2009, the Company recorded interest expense and related accrued interest payable of \$8,107 (See Note 6 (C)). An additional a payment of \$10,000 was made on October 19, 2009 (See Note 9 ).

As of September 30, 2009 the Company owes \$498,709 in accrued salary to principal stockholder. On October 10, 2008, the Company entered into an addendum to the employment agreement whereby all unpaid back salary will accrue interest at 7% per year. At September 30, 2009, the Company recorded interest expense and related accrued interest payable of \$28,897. In addition, the Company granted the CEO the right to convert any accrued salary into Class "A" Common Stock at either 1) The lowest price at which the Company's Class "A" Common Stock has traded over the preceding twelve month period, 2) At the lowest bid price for the preceding thirty days, 3) The lowest price paid in cash for the Class "A" Common Stock during the twelve months preceding the conversion. The conversion price for all salary accrued through March 1, 2009 is the lessor of options 1-3 or \$.002. The lowest stock price to convert the liability was \$.008 for accrued salary from March 1, 2009 through September 30, 2009. As of September 30, 2009, no accrued salary has been converted to Class "A" Common Stock (See Note 7 (A)).

**NOTE 9**            **SUBSEQUENT EVENTS**

In preparing these financial statements, the Company has evaluated the events and transactions for potential recognition or disclosure through November 18, 2009, the date the financial statements were issued.

On October 19, 2009, the amount of \$10,000 was repaid by the Company to the officer for the related party accrued expenses (See Note 7 (C) and 8 ).

On November 19, 2009, the issuance of 239,486 shares was approved by the board of directors as partial payment for services previously provided to the Company by a consultant in accordance with a consulting agreement ( See Note 6 (C) and 7 (C)).

On November 3, 2009, under the license agreement dated May 8, 2006, the company received a refund of \$23,900 for the overpayment of research fees (See Note 4 and 7 (B)).

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### Caution Regarding Forward-Looking Information

Certain statements contained herein, including, without limitation, statements containing the words “believes”, “anticipates”, “expects” and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: international, national and local general economic and market conditions; demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other factors referenced in this and previous filings.

Given these uncertainties, readers of this prospectus and investors are cautioned not to place undue reliance on such forward-looking statements.

### Plan of Operations

During the next twelve months, we expect to take the following steps in connection with the further development of our business and the implementation of our plan of operations:

- » We expect to spend up to \$35,000 per quarter through March 2010 on collaborative research and development of high strength polymers at the University of Notre Dame. We believe that this research is essential to our product development. If our financing will allow, management will give strong consideration to accelerating the pace of spending on research and development within the University of Notre Dame's laboratories.
- » We expect to spend approximately \$13,700 on collaborative research and development of high strength polymers and spider silk protein at the University of Wyoming over the next twelve months. We believe that this research is important to our product development. This level of research spending at the university is also a requirement of our licensing agreement with the university. If our financing will allow, management will give strong consideration to accelerating the pace of spending on research and development within the University of Wyoming's laboratories.
- » We will actively consider pursuing collaborative research opportunities with other university laboratories in the area of high strength polymers. If our financing will allow, management will give strong consideration to increasing the depth of our research to include polymer production technologies that are closely related to our core research
- » We will consider buying an established revenue producing company which is operating in the biotechnology arena, in order to broaden our financial base and increase our research and development capability. We expect to use a combination of stock and cash for any such purchase.
- » We will also actively consider pursuing collaborative research opportunities with university laboratories in areas of research which overlap the company's existing research and development. One such potential area for collaborative research which the company is considering is protein expression platforms. If our financing will allow, management will give strong consideration to increasing the breadth of our research to include protein expression platform technologies.

### Limited Operating History

We have not previously demonstrated that we will be able to expand our business through an increased investment in our research and development efforts. We cannot guarantee that the research and development efforts described in this Registration Statement will be successful. Our business is subject to risks inherent in growing an enterprise, including limited capital resources,

risks inherent in the research and development process and possible rejection of our products in development.

If financing is not available on satisfactory terms, we may be unable to continue expanding our operations. Equity financing will result in a dilution to existing shareholders.

**Results of Operations for the Three Months ended September 30, 2009 as Compared to the Three Months ended September 30, 2008.**

Revenue for the three months ended September 30, 2009 was \$0. This compares to \$0 in revenue for the three months ended September 30, 2008. No sales are anticipated during the next twelve months as we will remain in the development stage.

Operating expenses for the three months ended September 30, 2009 was \$ 80,670 . This compares to \$71,998 in expenses during the three months ended September 30, 2008. Research and development expenses for the three months ended September 30, 2009 were \$5,946. This compares to \$5,945 spent on research and development during the three months ended September 30, 2008. In addition, we had the following expenses during the three months ended September 30, 2009: general and administrative \$ 12,785 , professional fees \$6,785 and officer's salary \$55,154. This compares to the same expenses during the three months ended September 30, 2008: general and administrative \$8,383, professional fees \$4,765 and officer's salary \$52,905.

Total Other Income increased from \$0 for the three months ending September 30, 2008 to \$ 396,770 for the three months ended September 30, 2009 . This 100% increase is solely due to the recognition of derivative income for the three months ending September 30, 2009 for the convertible accrued salary owed to the CEO.

**Results of Operations for the Nine months ended September 30, 2009 as Compared to the Nine Months ended September 30, 2008.**

Revenue for the nine months ended September 30, 2009 was \$0. This compares to \$0 in revenue for the nine months ended September 30, 2008. No sales are anticipated during the next twelve months as we will remain in the development stage.

Operating expenses for the nine months ended September 30, 2009 was \$ 298,848 . This compares to \$276,842 in expenses during the nine months ended September 30, 2008. Research and development expenses for the nine months ended September 30, 2009 were \$63,854. This compares to \$27,131 spent on research and development during the nine months ended September 30, 2008. In addition, we had the following expenses during the nine months ended September 30, 2009: general and administrative \$ 38,235 , professional fees \$22,824 and officer's salary \$173,935. This compares to the same expenses during the nine months ended September 30, 2008: general and administrative \$57,831, professional fees \$27,211 and officer's salary \$164,669.

Total Other Expenses increased from \$2,781 of other income for the nine months ending September 30, 2008 to other expenses of \$ 1,833,117 . This increase in total other expense is due to the change in fair value of embedded derivative liability for the nine months ending September 30, 2009 for the convertible accrued salary owed to the CEO.

**Capital Resources and Liquidity**

As of September 30, 2009 we had \$34,119 in cash compared to \$9,537 as of December 31, 2008.

We believe we can not satisfy our cash requirements for the next twelve months with our current cash. Completion of our plan of operation is subject to attaining adequate financing. We cannot assure investors that adequate financing will be available. In the absence of such financing, we may be unable to proceed with our plan of operations.

We anticipate that our operational, and general & administrative expenses for the next 12 months will total approximately \$400,000. We do not anticipate the purchase or sale of any significant equipment. We also do not expect any significant additions to the number of employees. The foregoing represents our best estimate of our cash needs based on current planning and business conditions. The exact allocation, purposes and timing of any monies raised in subsequent private financings may vary significantly depending upon the exact amount of funds raised and our progress with the execution of our business plan.

In the event we are not successful in obtaining financing, we may not be able to proceed with our business plan for the research and development of our products. We anticipate that we will incur operating losses in the foreseeable future. Therefore, our auditors have raised substantial doubt about our ability to continue as a going concern.

On March 23, 2009, the Company's Board of Directors declared a nine-for-one stock split to be effected in the form of a stock dividend. The stock dividend was distributed to shareholders of record on April 27, 2009. A total of 449,773,650 shares of common stock were issued. All basic and diluted loss per share and average shares outstanding information has been adjusted to

reflect the aforementioned stock dividend.

### **Critical Accounting Policies**

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States (“GAAP”). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Our significant accounting policies are summarized in Note 1 of our financial statements. While all these significant accounting policies impact its financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause effect on our results of operations, financial position or liquidity for the periods presented in this report.

### **Recent Accounting Pronouncements**

In May 2009, the FASB issued FASB Accounting Standards Codification No. 855, *Subsequent Events*. FASB Accounting Standards Codification No. 855 establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. FASB Accounting Standards Codification No. 855 sets forth (1) The period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements, (2) The circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements and (3) The disclosures that an entity should make about events or transactions that occurred after the balance sheet date. FASB Accounting Standards Codification No. 855 is effective for interim or annual financial periods ending after September 15, 2009. The adoption of this FASB Accounting Standards Codification No. did not have a material effect on the Company's financial statements.

In June 2009, the FASB issued FASB Accounting Standards Codification No. 860, *Transfers and Servicing*. FASB Accounting Standards Codification No. 860 improves the relevance, representational faithfulness, and comparability of the information that a reporting entity provides in its financial statements about a transfer of financial assets; the effects of a transfer on its financial position, financial performance, and cash flows; and a transferor's continuing involvement, if any, in transferred financial assets. FASB Accounting Standards Codification No. 860 is effective as of the beginning of each reporting entity's first annual reporting period that begins after November 15, 2009, for interim periods within that first annual reporting period and for interim and annual reporting periods thereafter. The Company is evaluating the impact the adoption that FASB Accounting Standards Codification No. 860 will have on its financial statements.

In June 2009, the FASB issued FASB Accounting Standards Codification No. 810, *Consolidation*. FASB Accounting Standards Codification No. 810 improves financial reporting by enterprises involved with variable interest entities. FASB Accounting Standards Codification No. 810 is effective as of the beginning of each reporting entity's first annual reporting period that begins after November 15, 2009, for interim periods within that first annual reporting period, and for interim and annual reporting periods thereafter. The Company is evaluating the impact the adoption of FASB Accounting Standards Codification No. 810 will have on its financial statements.

In June 2009, the FASB issued FASB Accounting Standards Codification No. 105, *GAAP*. The FASB Accounting Standards Codification ("Codification") will be the single source of authoritative nongovernmental U.S. generally accepted accounting principles. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. FASB Accounting Standards Codification No. 105 is effective for interim and annual periods ending after September 15, 2009. All existing accounting standards are superseded as described in FASB Accounting Standards Codification No. 105. All other accounting literature not included in the Codification is nonauthoritative. The adoption of the Codification did not have a significant impact on the Company's financial statements.

**Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as “special purpose entities” (SPEs).

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Not required for Smaller Reporting Companies.

**Item 4T. Controls and Procedures**

a) *Evaluation of Disclosure Controls.* Our Chief Executive Officer and Chief Financial and Accounting Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of our three months ended September 30, 2009 pursuant to Rule 13a-15(b) of the Securities and Exchange Act. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Exchange Act is accumulated and communicated to our management, as appropriate to allow timely decisions regarding required disclosure. Based on his evaluation, the CEO and CFO concluded that our disclosure controls and procedures were not. Specifically the Company did not properly account for derivative liability associated with our CEO’s accrued salary.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

(b) *Changes in internal control over financial reporting.* In order to rectify our ineffective disclosure controls and procedures, we are developing a plan to ensure that all information will be recorded, processed, summarized and reported accurately, and as of the date of this report, we have taken the following steps to address the above-referenced material weaknesses in our internal control over financial reporting:

1. We will continue to educate our management personnel to comply with the disclosure requirements of Securities Exchange Act of 1934 and Regulation S-K; and
2. We will increase management oversight of accounting and reporting functions in the future.

**PART II - OTHER INFORMATION****Item 1. Legal Proceedings.**

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

**Item 1A. Risk Factors.**

None.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

On July 1, 2009, the Company issued 280,000 shares to Dr. Jarvis as repayment for services previously provided to the Company by a consultant having a fair value of \$14,000 (\$0.05/share) in accordance with a consulting agreement.

On July 1, 2009, the Company issued 482,825 shares of common stock to Dr. Fraser as partial payment for services previously provided to the Company by a consultant in accordance with a consulting agreement.

On September 30, 2009, the Company issued 366,599 shares of common stock for \$3,000 (\$.008/share) to Sam Ching.

*The issuance of these securities were exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended, and Regulation D promulgated under the Securities Act of 1933, as amended.*

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Submission of Matters to a Vote of Security Holders.**

None.

**Item 5. Other Information.**

None.

**Item 6. Exhibits.**

(a) Exhibits

31.1 Certifications pursuant to Section 302 of Sarbanes Oxley Act of 2002

32.1 Certifications pursuant to Section 906 of Sarbanes Oxley Act of 2002

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**KRAIG BIOCRAFT LABORATORIES, INC.**

Date: May 28 , 20 1 0

By: /s/ Kim Thompson  
Kim Thompson  
Chief Executive Officer